Skip to content
Calculator
Regulatory

Peptide laws in Japan

Last updated: October 3, 2026 · 4 min read · By the Grey Peptides Editorial Board

Tokyo cityscape at twilight
Photo by Guohua Song on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • On June 16, 2026, Japan's health ministry told manufacturers and prefectures to curb off-label cosmetic and weight-loss use of GLP-1 and GIP/GLP-1 drugs.
  • Japan allows limited personal import of medicines: prescription drugs up to one month's supply, and syringes only with a prescription or doctor's instruction.
  • No research peptide such as BPC-157 is an approved medicine in Japan.
  • Each status on this page is dated and sourced.

How Japan regulates peptides

Japan regulates medicines under its Pharmaceuticals and Medical Devices Act, administered by the Ministry of Health, Labour and Welfare (MHLW) with the Pharmaceuticals and Medical Devices Agency (PMDA). Only licensed marketing authorisation holders may import medicines as a business; individuals may import limited quantities for their own use 1. Approved peptide medicines, such as the GLP-1 drugs, are prescribed for their approved indications 2.

The June 2026 notice on GLP-1 drugs

On June 16, 2026, the MHLW issued notices to manufacturers and to prefectures on the proper use of GLP-1 and GIP/GLP-1 receptor agonists approved as treatments for type 2 diabetes or obesity. According to the trade press reports, the ministry acted because off-label use for cosmetic and weight-loss purposes, not their approved treatment purposes, had become widespread at some medical institutions, and it warned that off-label use can lead to unexpected adverse events 2. The manufacturer notices were addressed to Eli Lilly Japan, which markets tirzepatide (Mounjaro), and Novo Nordisk Pharma, which markets semaglutide (Wegovy) for obesity, asking them to issue alerts working with distributors 2. Prefectures were directed to have medical institutions strengthen their systems and strictly follow the medical advertising guidelines, which in principle prohibit advertising private treatment with drugs that are unapproved in Japan or used off-label 2.

Personal import: limits and prescriptions

Japan Customs sets out the quantities individuals may import for personal use without a further check: for medicines other than external preparations, up to one month's supply of poisonous, powerful or prescription drugs, and up to two months' supply of other medicines; external preparations are limited to 24 items per product, excluding prescription ones 1. Customs adds that certain ingredients, including some sold abroad with claims of improving brain function, may not be imported by individuals in any quantity without confirmation of a doctor's prescription 1.

Injecting is a further hurdle. The MHLW's Kinki regional bureau explains that syringes and needles may be imported for use with a medicine approved for self-injection only where there is a doctor's prescription or instruction, through an import confirmation application 3. The ministry's import page warns that medicines bought abroad have not been checked for quality, efficacy and safety under Japanese law and may make false or exaggerated claims 4.

Research peptides

Research peptides such as BPC-157, TB-500 and GHK-Cu are not approved medicines in Japan. We did not find an MHLW statement specific to them, so this page does not describe one. The personal-import rules above apply to medicines, and the syringe rule makes importing injecting equipment without a prescription problematic 3.

Sport

Japanese athletes follow the WADA Prohibited List through the Japan Anti-Doping Agency. BPC-157 is prohibited under S0, and growth hormone secretagogues and releasing peptides are named under S2.2.4 5. Our WADA hub lists each peptide.

Japan in context

Japan's June notice is part of a wider 2026 pattern of regulators pushing back on GLP-1 drugs used outside their approvals, alongside warnings in the EU and the UK. Our UK page and EU page describe those, and our semaglutide brands guide explains what each approved product is for.

Questions to check

  • Is the medicine approved in Japan for the use I am being offered it for?
  • Does a clinic's advertising promote off-label or unapproved drugs, which the guidelines in principle prohibit?
  • Am I importing within the personal-use limits, with a prescription where required?
  • Does importing injecting equipment need a prescription and import confirmation?
  • Am I subject to anti-doping rules?

The bottom line

Japan treats approved peptide medicines as prescription drugs and, in June 2026, told manufacturers and prefectures to curb their off-label cosmetic and weight-loss use. Personal import is allowed within limits, one month's supply for prescription drugs, and syringes need a prescription. Research peptides are not approved medicines in Japan.

Frequently asked questions

Are peptides legal in Japan?

Approved peptide medicines are legal on prescription for their approved uses. Research peptides such as BPC-157 are not approved medicines in Japan.

Can I use GLP-1 drugs for weight loss in Japan?

In June 2026 the health ministry acted against off-label cosmetic and weight-loss use of GLP-1 and GIP/GLP-1 drugs approved for type 2 diabetes or obesity.

How much medicine can I import into Japan for personal use?

Japan Customs allows up to one month's supply of prescription, poisonous or powerful drugs and up to two months' supply of other medicines; some ingredients need a prescription in any quantity.

Can I import syringes into Japan?

Only for a medicine approved for self-injection, with a doctor's prescription or instruction, through an import confirmation application.

Sources

  1. Japan Customs. Customs Answer 9005: travellers bringing in medicines and cosmetics (personal import quantities). Read October 3, 2026. Source
  2. Ministry of Health, Labour and Welfare. Notices on the proper use of GLP-1 receptor agonists and GIP/GLP-1 receptor agonists, June 16, 2026, as reported by Yakuji Nippo (June 19, 2026) and Japan Medical Journal. Read October 3, 2026.
  3. MHLW Kinki Regional Bureau of Health and Welfare. When a postcard arrives from customs (individuals): syringes and needles. Read October 3, 2026. Source
  4. Ministry of Health, Labour and Welfare. To those considering buying medicines from overseas: risks of personal import. Read October 3, 2026. Source
  5. Grey Peptides WADA hub (2026 Prohibited List). Read October 3, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All countries

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead